Description
WHAT IS HCG 5000 IU
LH activity is present in highly purified human chorionic gonadotrophin. Normal female and male gamete growth and maturation, as well as gonadal steroid synthesis, require LH. steroidsweden.com sells the best brands in europe qnd we delivery in the whole of europe without any problem
In the female, Human Chorionic Gonadotrophin is used to trigger the final phase of follicular maturation, which leads to ovulation, in place of the endogenous mid-cycle LH surge. During the luteal phase, human chorionic gonadotrophin is used to replace natural LH.
Human Chorionic Gonadotrophin is administered to males to stimulate Leydig cells and enhance testosterone synthesis.
Pharmacokinetic Properties: Human Chorionic Gonadotrophin plasma levels reach their maximum six hours after a single injection. Human Chorionic Gonadotrophin is processed to an extent of around 80%, primarily in the kidneys. Human Chorionic Gonadotrophin has an apparent elimination half-life of around 2 days after intramuscular injection (IM). Accumulation does not occur based on the suggested dosing regimens and elimination half-life.
In the female:
Ovulation induction in infertility due to anovulation or impaired follicle-ripening.
Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (ART).
Luteal phase support.
Threatened and habitual abortion.
In the male:
Hypogonadotropic hypogonadism (also cases of idiopathic dyspermias have shown a positive response to gonadotropins).
Used to treat oligospermia.
Delayed puberty associated with insufficient gonadotropic pituitary function.
Dosage & Administration
Injection provided, immediately prior to use.
In the female :
Anovulatory infertility : HCG 5000 IU IM/SC Injection is administered in mid-cycle, following treatment with Menotrophin Inj. according to a recognized scheme. Details of Menotrophin Inj. Dosage and monitoring are available on request.
Luteal phase support : Two repeat injections of 2500 IU to 5000 IU. Each may be given within nine days following ovulation or embryo transfer (for example on day 3, 6 and 9 after ovulation induction).
In the male : Oligospermia: 2500 IU to 5000 IU HCG, twice per week. During this treatment testosterone replacement therapy should be suspended. Hypogonadotropic hypogonadism: 2500 IU to 5000 IU HCG, twice per week.
If the main complaint is sterility, additional doses of an FSH-containing (75 IU FSH or 75 IU HMG) are to be administered daily or two to three times a week. This treatment should be continued for at least three months before any improvement in spermatogenesis can be expected. During this treatment testosterone replacement therapy should be suspended. Once achieved, the improvement may in some cases be maintained by HCG alone.
https://buysteroidaustralia.com/
Precautions
In pregnancies occurring after induction of ovulation with gonadotropic preparations, there is an increased risk of multiplets birth.
Unwanted ovarian hyperstimulation: In patients treated for infertility due to anovulation or impaired follicular ripening, the prior administration of an FSH containing preparation may lead to unwanted ovarian hyperstimulation. Therefore ultrasonic assessment of follicular development and determinations of estrogen levels should be performed prior to FSH-treatment and at regular intervals during FSH-treatment. Estrogen levels may rise very rapidly, eg more than a daily doubling for two or three consecutive days, and possibly reach excessively high values. If this unwanted ovarian hyperstimulation occurs (ie not as part of a treatment preparing for IVF/ET or GIFT/ZIFT), the administration of the FSH-containing preparation should be discontinued immediately. In that case Human Chorionic Gonadotrophin must not be given, Because the administration of an LH-active gonadotrophin at this stage may induce, in addition to multiple ovulations, the ovarian hyperstimulation syndrome. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy. which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy. which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy
Reviews
There are no reviews yet.